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Abstract
One hundred and three patients who had previously tested posi-
tive for community-acquired methicillin-resistant Staphylococcus
aureus (cMRSA) were followed up for a mean time of
32.6 months. Eighty patients had a history of skin or soft tissue
infection, and the remainder were mostly asymptomatic carriers.
Of 103 patients, only two reported ongoing symptoms with
abscess formation. Of 81 nasal swabs available, 30.9% were posi-
tive for S. aureus but only four yielded Panton–Valentine leukoci-
din-positive methicillin-resistant S. aureus. In summary, we were
unable to ﬁnd persistent health issues or nasal colonization with
cMRSA in a cohort of previously cMRSA-infected/colonized
patients.
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The spread of methicillin-resistant Staphylococcus aureus
(MRSA) is of increasing health concern. Whereas MRSA has
been traditionally conﬁned to hospitals and other healthcare
institutions, increasing numbers of community-acquired MRSA
(cMRSA) isolates have been detected in recent years. cMRSA
isolates differ from hospital-associated isolates in their anti-
biotic resistance patterns and expression of pathogenicity fac-
tors. Isolates generally possess smaller (and supposedly more
mobile) SCCmec elements, encoding for fewer resistance
genes. However, many cMRSA isolates seem to be highly viru-
lent, are associated with skin and soft tissue infections, and
express virulence factors such as Panton–Valentine leukocidin
(PVL), a-toxin and phenol-soluble modulins (reviewed in [1]).
Contemporary cMRSA isolates are thought to have
emerged world wide from different clonal lineages [2].
Although cMRSA isolates are highly prevalent among isolates
from skin and soft tissue infections in some settings, the exact
reservoir remains a matter of debate. We followed up patients
who had tested positive for cMRSA, mostly during skin or soft
tissue infections. Isolates were identiﬁed as cMRSA on the
basis of a lack of healthcare association, PCR screening for the
presence of PVL [3] and resistance to methicillin. Most isolates
were also resistant to fusidic acid, a resistance pattern that is
frequently found among central European cMRSA isolates [4].
During previous outbreaks, most PVL-positive cMRSA isolates
in the area were shown by multilocus sequence typing to
belong to the sequence types ST80 and ST22 [5].
Between May 2007 and September 2008, 103 patients
with a previously collected sample that was positive for
cMRSA were contacted. cMRSA had been diagnosed 4–145
months previously (mean 32.6 months). All patients were
sent nasal swabs and a standardized questionnaire, and were
interviewed by telephone. Specimens were plated after pre-
enrichment in thioglycolate broth onto non-selective and
selective media.
The mean age at diagnosis of cMRSA was 35.4 years
(range 2–81 years); 43.7% of participants were male, and 13
were children below 18 years of age (a summary of demo-
graphic characteristics is given in Table 1). Nine respondents
were retired, 14 healthcare workers, and other occupations
were evenly distributed; 28.6% reported smoking regularly,
and 45.4% reported alcohol consumption; 11.2% visited sau-
nas or other wellness institutions on a regular basis; another
11.2% participated in sports with close body contact.
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A majority of participants (68%) had travelled to foreign
countries (and almost half of these to non-European destina-
tions). We have previously identiﬁed several cMRSA isolates
related to travel or foreign origin, mostly to the Middle East
[6]. It is interesting to note that almost two-thirds (63.9%)
of all study participants reported close contact with domestic
animals. Apart from pigs and horses [7], companion animals
have been described as a potential reservoir for MRSA in
the community [8]. Forty per cent of all respondents were
receiving regular medical or dental care, and 48% reported
regular use of prescription drugs (among these, only three
patients received glucocorticoids; no other immunosuppres-
sives were identiﬁed). Skin disease (other than abscesses)
was frequent (24.5%) and comprised mostly eczema, psoria-
sis and neurodermatitis. Although a history of abscesses was
highly prevalent (77.7% reported at least one abscess initially
and two-thirds (63.3%) multiple abscesses, and one patient
each had osteomyelitis and pneumonia), only two patients
reported active abscesses at the time of interview (nasal
swabs of these patients returned one methicillin-sensitive
S. aureus isolate and one negative sample).
Out of 103 swab kits sent to participants, 81 nasal swabs
were returned and 25 (30.9%) were culture-positive for
S. aureus. Microbiological results are presented in Table 2.
The carrier rate for S. aureus was not signiﬁcantly different
between groups without initial documented treatment
(n = 15), surgical treatment only (mostly abscess drainage,
n = 10), medical therapy only (n = 16) or combined medical
and surgical therapy (n = 40). Only four of 81 patients were
still tested positive for cMRSA, all belonging to a cluster
within a single family. Three of these four patients who were
still positive for cMRSA had not received any surgical or
medical treatment (p 0.018 vs. treated patients). Only in 20%
of patients could effective antibiotic therapy for cMRSA be
documented retrospectively (mostly a combination of co-
trimoxazole and rifampicin, or clindamycin with mupirocin
ointment). A similar number (n = 3) of PVL-negative MRSA
isolates were found. This might reﬂect either the presence
of additional PVL-negative strains in the community or an
increased blurring of the traditional niches of community-
associated vs. hospital-associated strains.
Whereas overall colonization with S. aureus is in the range
of colonization found by studies in the general population
[9], the low rate of nasal colonization with cMRSA in this
preselected cohort seems striking. Although nasal carriage of
S. aureus has been associated with subsequent invasive infec-
tions [10], cMRSA isolates may cause infection in the
absence of nasal colonization. Other body sites of coloniza-
tion may include the axilla, the groin, the perirectal area and
wounds. Sampling at further sites may be necessary to
exclude the possibility of colonization of body sites other
than anterior nares. Moreover, cMRSA may be more trans-
missible and spread more rapidly by close person-to-person
contacts [11]. In addition, it is important to note that clonal
cMRSA lineages are heterogenous, and isolates that are pre-
valent in other regions of the world may express factors
responsible for different transmission and colonization pat-
terns (e.g. the ACME gene cluster in the most prevalent
North American strain, USA300 [12]).
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TABLE 1. Patient (n = 103) demographics at the time of
ﬁrst community-acquired methicillin-resistant Staphylococ-
cus aureus diagnosis
General
Age (years), mean (range) 35.4 (2–81)
Male 43.7%
Healthcare workers 13.6%
Smoking 28.6%
Alcohol consumption 45.4%
Contact with domestic animals 63.9%
Sport (with body contact) 11.2%
Travel history to foreign countries 68%
Travel history to non-European countries 33%
Medical conditions
Regular medical attendance 40%
Regular dental care 40%
(Prescription) drugs 48%
Allergies 34.7%
History of any type of surgery 85%
Any type of skin disease (not abscess) 24.5%
History of abscesses 77.7%
Multiple abscesses 63.3%
TABLE 2. Microbiological results from nasal swabs
MSSA,
PVL-ngative
MSSA,
PVL-positive
MRSA,
PVL-negative
MRSA,
PVL-positive
Staphylococcusaureus
total, no. (%)
Total (n = 81) 12 6 3 4 25 (30.9)
No documented treatment (n = 15) 1 1 2 3 7 (46.7)
Surgical treatment only (n = 10) 2 2 – – 4 (40)
Medical treatment only (n = 16) 3 2 1 – 6 (37.5)
Medical + surgical treatment (n = 40) 6 1 – 1 8 (20)
MRSA, methicillin-resistant S. aureus; MSSA, methicillin-sensitive S. aureus; PVL, Panton–Valentine leukocidin.
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